Table 1.

Indications for Helicobacter pylori Eradication in Korea and the United States

Strength of recommendations	Korea	United States
		ACG	Houston Consensus Conference
Strong recommendations	Peptic ulcer disease Gastric MALT lymphoma History of endoscopic resection of early gastric cancer Idiopathic thrombocytopenic purpura Long-term low-dose aspirin user with a history of peptic ulcer	All patients with active H. pylori infection Active peptic ulcer disease Low-grade gastric MALT lymphoma History of endoscopic resection of early gastric cancer Functional dyspepsia Patients with typical GERD symptoms who do not have a peptic ulcer disease history* Patients starting chronic treatment with a NSAID	All patients with active H. pylori infection Peptic ulcer disease Gastric MALT lymphoma Uninvestigated dyspepsia Patients with reflux symptoms (only if they have high risk for H. pylori-related disease) Idiopathic thrombocytopenic purpura Family history of gastric cancer Family history of peptic ulcer disease First-generation immigrants from high prevalence areas Family members residing in the same household of patients with proven active H. pylori infections
Weak recommendations	Family history of gastric cancer Functional dyspepsia Unexplained iron deficiency anemia History of endoscopic resection of gastric adenoma	Uninvestigated dyspepsia Long-term low-dose aspirin user Unexplained iron deficiency anemia Idiopathic thrombocytopenic purpura	Latino and African American racial or ethnic groups Long-term PPI user (>1 month) Long-term aspirin/NSAID user (>1 month) Patients treated with medications whose absorption is known to be impacted by infection (e.g., levodopa, thyroxin)

ACG, American College of Gastroenterology; MALT, mucosa-associated lymphoid tissue; GERD, gastroesophageal reflux disease; NSAID, nonsteroidal anti-inflammatory drug; PPI, proton pump inhibitor.

*The ACG guidelines strongly recommend that these patients do not need to be tested for H. pylori infection.